SAN DIEGO, May 09, 2007 — Conatus Pharmaceuticals Inc. today completed the $22 million second closing of the $27.5 million Series A Preferred Stock private placement announced in January this year. This closing is associated with the achievement of a pre-clinical milestone with CTS-1027, the Company’s novel clinical stage drug candidate. “CTS-1027 is a potent […]

SAN DIEGO, June 24, 2009 — Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with approved standard of care treatments is not currently […]

SAN DIEGO, July 12, 2012 — Conatus Pharmaceuticals Inc. announced today the appointment of Mark F. Morris as Head of Biostatistics effective immediately. In this newly created position, Mr. Morris will oversee the statistical design of the company’s human clinical trials. “Mark provides an enormous amount of technical expertise in statistical design and analysis,” said […]